Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.63 |
| ▸ | MEN1 | O00255 | 7/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101197 | 0.86 | EPHX2 (0.67) | KMT2AMEN1ALDH1A1GAAEPHX2 | |
| SCHEMBL4107987 | 0.85 | EPHX2 (0.57) | KMT2AMEN1ALDH1A1EPHX2MAPT | |
| SCHEMBL4113222 | 0.82 | EPHX2 (0.65) | KMT2AALDH1A1EPHX2MAPTPOLB | |
| SCHEMBL4113279 | 0.81 | EPHX2 (0.65) | KMT2AMEN1ALDH1A1GAAEPHX2 | |
| SCHEMBL4109109 | 0.80 | EPHX2 (0.68) | KMT2AMEN1ALDH1A1GAAEPHX2 | |
| SCHEMBL4112972 | 0.79 | EPHX2 (0.70) | KMT2AMEN1EPHX2MAPTNPC1 | |
| SCHEMBL12218290 | 0.78 | KMT2A (1.00) | KMT2AMEN1ALDH1A1GAACYP2C19 | |
| SCHEMBL18500908 | 0.77 | ALDH1A1 (0.74) | KMT2AMEN1ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL4107258 | 0.76 | EPHX2 (0.58) | EPHX2CYP1A2CYP2C19MAPTKDM4E | |
| SCHEMBL10755457 | 0.75 | KMT2A (0.69) | KMT2AMEN1ALDH1A1GAATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960352-B1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-07 | — | — | EP | claimed |
| US-8466200-B2 | 2-adamantylurea derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2013-06-18 | — | — | US | claimed |
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-05 | — | — | US | claimed |
| US-8188288-B2 | 2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-29 | — | — | US | claimed |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-10 | — | — | US | claimed |
| EP-1960352-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2008-08-27 | — | — | EP | claimed |
| EP-1801098-A1 | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors | Merck Sante (FR) | 2007-06-27 | — | — | EP | claimed |
| WO-2007068330-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2007-06-21 | — | — | WO | claimed |
| EP-1960352-B1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-8466200-B2 | 2-adamantylurea derivatives as selective 11β-HSD1 inhibitors | MERCK PATENT GMBH (DE) | 2013-06-18 | — | — | US | disclosed |
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-07-05 | — | — | US | disclosed |
| US-8188288-B2 | 2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-05-29 | — | — | US | disclosed |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-10 | — | — | US | disclosed |
| EP-1960352-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | Merck Patent GmbH (DE) | 2008-08-27 | — | — | EP | disclosed |
| EP-1801098-A1 | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors | Merck Sante (FR) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007068330-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11β-HSD1 INHIBITORS | MERCK PATENT GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172396-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11B-HSD1 INHIBITORS | HSD11B1, HSD11B2, HSD17B1 | KMT2A 3448/4885MEN1 1029/4885ALDH1A1 90/4885 |
| US-20090227631-A1 | 2-ADAMANTYLUREA DERIVATIVES AS SELECTIVE 11BETA-HSD1 INHIBITORS | HSD11B1, HSD11B2, HSD17B1 | KMT2A 3706/4885MEN1 996/4885ALDH1A1 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.